所有的路都通向靶向弥漫性大 B 细胞淋巴瘤的方法。
All roads lead to targeted diffuse large B-cell lymphoma approaches.
机构信息
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China.
出版信息
Cancer Cell. 2022 Feb 14;40(2):131-133. doi: 10.1016/j.ccell.2022.01.013.
Two recent reports in the New England Journal of Medicine highlight the successful application of novel targeted therapies to improve the clinical outcomes of diffuse large B-cell lymphoma (DLBCL). These findings encourage us to pursue further mechanism-based therapeutic uses to make DLBCL curable in the era of precision medicine.
最近在《新英格兰医学杂志》上发表的两项研究报告强调了新型靶向治疗在改善弥漫性大 B 细胞淋巴瘤（DLBCL）的临床结果方面的成功应用。这些发现鼓励我们进一步探索基于机制的治疗用途，以使 DLBCL 在精准医学时代成为可治愈的疾病。
Zotero 插件